[go: up one dir, main page]

DK1308166T3 - Ikke-neurotoksisk plasminogenaktiverende faktorer til behandling af slagtilfælde - Google Patents

Ikke-neurotoksisk plasminogenaktiverende faktorer til behandling af slagtilfælde

Info

Publication number
DK1308166T3
DK1308166T3 DK01130006T DK01130006T DK1308166T3 DK 1308166 T3 DK1308166 T3 DK 1308166T3 DK 01130006 T DK01130006 T DK 01130006T DK 01130006 T DK01130006 T DK 01130006T DK 1308166 T3 DK1308166 T3 DK 1308166T3
Authority
DK
Denmark
Prior art keywords
stroke
treatment
plasminogen activating
activating factors
activity
Prior art date
Application number
DK01130006T
Other languages
English (en)
Inventor
Wolf-Dieter Schleuning
Robert Medcalf
Mariola Soehngen
Wolfgang Soehngen
Original Assignee
Paion Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion Deutschland Gmbh filed Critical Paion Deutschland Gmbh
Application granted granted Critical
Publication of DK1308166T3 publication Critical patent/DK1308166T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
DK01130006T 2001-11-02 2001-12-17 Ikke-neurotoksisk plasminogenaktiverende faktorer til behandling af slagtilfælde DK1308166T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10153601A DE10153601A1 (de) 2001-11-02 2001-11-02 DSPA zur Behandlung von Schlaganfall

Publications (1)

Publication Number Publication Date
DK1308166T3 true DK1308166T3 (da) 2009-12-14

Family

ID=7704253

Family Applications (3)

Application Number Title Priority Date Filing Date
DK01130006T DK1308166T3 (da) 2001-11-02 2001-12-17 Ikke-neurotoksisk plasminogenaktiverende faktorer til behandling af slagtilfælde
DK08012976.0T DK1997510T3 (da) 2001-11-02 2002-10-31 Ikke-neurotoksiske plasminogen-aktiverende faktorer til behandling af et slagtilfælde
DK02785348T DK1441757T3 (da) 2001-11-02 2002-10-31 Ikke-neurotoksiske plasminogenaaktiverende faktorer til behandling af slagtilfælde

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK08012976.0T DK1997510T3 (da) 2001-11-02 2002-10-31 Ikke-neurotoksiske plasminogen-aktiverende faktorer til behandling af et slagtilfælde
DK02785348T DK1441757T3 (da) 2001-11-02 2002-10-31 Ikke-neurotoksiske plasminogenaaktiverende faktorer til behandling af slagtilfælde

Country Status (26)

Country Link
US (7) US20050048027A1 (da)
EP (4) EP1308166B1 (da)
JP (2) JP5004407B2 (da)
KR (3) KR20070087248A (da)
CN (2) CN101156948A (da)
AT (3) ATE440614T1 (da)
AU (1) AU2002350660C1 (da)
BR (1) BR0213856A (da)
CA (1) CA2465792C (da)
CY (3) CY1108446T1 (da)
DE (3) DE10153601A1 (da)
DK (3) DK1308166T3 (da)
EA (3) EA010858B1 (da)
ES (3) ES2332576T3 (da)
HR (1) HRP20040383B1 (da)
HU (1) HU230163B1 (da)
IL (1) IL205695A0 (da)
MX (1) MXPA04004155A (da)
NO (1) NO329789B1 (da)
NZ (2) NZ532903A (da)
PL (1) PL208343B1 (da)
PT (3) PT1308166E (da)
SG (1) SG148034A1 (da)
SI (2) SI1441757T1 (da)
WO (1) WO2003037363A2 (da)
ZA (1) ZA200403285B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
PL1622639T3 (pl) * 2003-05-02 2013-06-28 Lundbeck H As Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
WO2004096267A1 (de) * 2003-05-02 2004-11-11 Paion Gmbh Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
HRP20050898A2 (en) * 2003-05-05 2007-03-31 Paion Deutschland Gmbh Glutamate receptor antagonists as neuroprotectives
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
JP2006241109A (ja) * 2005-03-04 2006-09-14 Paion Deutschland Gmbh ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
EP2558580A2 (en) 2010-04-16 2013-02-20 H. Lundbeck A/S Method for the manufacture of recombinant dspa alpha1
CN103384722B (zh) * 2011-01-05 2016-11-16 斯路姆基因公司 纤溶酶原和纤溶酶变体
CN103764163A (zh) 2011-08-12 2014-04-30 斯路姆基因公司 纤溶酶原和纤溶酶变体
JP7604376B2 (ja) * 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68561A (en) 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
DE3643158A1 (de) 1986-04-21 1987-11-19 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
JPH087179B2 (ja) * 1986-09-27 1996-01-29 日本碍子株式会社 ガスセンサ
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
EP0386240B1 (en) * 1987-10-29 1995-07-19 Yamanouchi Pharmaceutical Co. Ltd. Novel polypeptide compounds
US5094953A (en) 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
FI100403B (fi) * 1988-07-20 1997-11-28 Schering Ag Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi
DE3825253A1 (de) 1988-07-25 1990-02-01 Boehringer Mannheim Gmbh T-pa-derivat und seine herstellung
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
JPH0273774A (ja) * 1988-09-09 1990-03-13 Nec Corp ファクシミリ装置
GB8901422D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co New tissue plasminogen activator
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
US6008019A (en) 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
DE3917949A1 (de) * 1989-05-30 1991-01-24 Schering Ag Neues thrombolytikum
DE3904580A1 (de) 1989-02-13 1990-08-16 Schering Ag Neues thrombolytikum
AU642404B2 (en) * 1989-02-13 1993-10-21 Schering Aktiengesellschaft Berlin Und Bergkamen Novel thrombolytic
AU652917B2 (en) * 1989-04-07 1994-09-15 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
JPH0352119A (ja) * 1989-07-19 1991-03-06 Matsushita Electric Ind Co Ltd 光学式記録再生装置
NL8902454A (nl) 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
DE4123845A1 (de) * 1991-07-18 1993-01-21 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
EP0580685B1 (de) * 1991-04-16 1996-01-03 Roche Diagnostics GmbH Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
NL9101520A (nl) * 1991-09-09 1993-04-01 Stork Fibron Bv Werkwijze voor het vervaardigen van een eetbaar produkt.
EP0618973B1 (en) 1991-12-16 1996-11-27 Genentech, Inc. t-PA SUBSTITUTION VARIANTS WITH IMPROVED FIBRIN-SPECIFICITY
JP3490444B2 (ja) * 1992-12-04 2004-01-26 シエーリング アクチエンゲゼルシヤフト 昆虫類の唾液からのトロンビン阻害剤
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
DE4423574A1 (de) 1994-07-05 1996-01-11 Boehringer Mannheim Gmbh Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
US6235947B1 (en) * 1997-04-14 2001-05-22 Takeda Chemical Industries, Ltd. D-mannitol and its preparation
US5830349A (en) * 1996-07-22 1998-11-03 Dana Corporation Flow inverter for filters
NZ334604A (en) * 1996-10-01 1999-11-29 American Cyanamid Co A DNA molecule containing a baculovirus promoter operable linked to a coding sequnce for an insect-specific toxin; biological insect control agents comprising the altered baculovirus
US6008109A (en) * 1997-12-19 1999-12-28 Advanced Micro Devices, Inc. Trench isolation structure having a low K dielectric encapsulated by oxide
KR20010069066A (ko) 2000-01-12 2001-07-23 이종원 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
DE10008646A1 (de) 2000-02-24 2001-09-13 Kempten Elektroschmelz Gmbh Beschichteter Formkörper aus Siliciumnitrid
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
US20020089179A1 (en) * 2000-12-30 2002-07-11 Levon Guyumjan Hose coupling apparatus and method
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
PL1622639T3 (pl) 2003-05-02 2013-06-28 Lundbeck H As Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu
WO2004096267A1 (de) 2003-05-02 2004-11-11 Paion Gmbh Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
HRP20050898A2 (en) * 2003-05-05 2007-03-31 Paion Deutschland Gmbh Glutamate receptor antagonists as neuroprotectives
US20050085478A1 (en) 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
DE10342518A1 (de) 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
AR068914A1 (es) 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia

Also Published As

Publication number Publication date
US20140199287A1 (en) 2014-07-17
EA010858B1 (ru) 2008-12-30
KR20050042234A (ko) 2005-05-06
EP1308166A1 (de) 2003-05-07
HU230163B1 (hu) 2015-09-28
DE50115077D1 (de) 2009-10-08
ATE401910T1 (de) 2008-08-15
US20060142195A1 (en) 2006-06-29
HUP0402165A2 (hu) 2005-01-28
NO329789B1 (no) 2010-12-20
BR0213856A (pt) 2004-08-31
JP2005519025A (ja) 2005-06-30
EP1997510B1 (de) 2012-02-29
EP1308166B1 (de) 2009-08-26
HUP0402165A3 (en) 2010-01-28
PL369872A1 (en) 2005-05-02
CA2465792C (en) 2014-04-01
HK1057328A1 (zh) 2004-04-02
CN101156948A (zh) 2008-04-09
ES2332576T3 (es) 2010-02-09
KR20070087248A (ko) 2007-08-27
PT1308166E (pt) 2009-11-27
SI1441757T1 (sl) 2009-02-28
PT1441757E (pt) 2008-11-03
KR20090128583A (ko) 2009-12-15
DE50212548D1 (de) 2008-09-04
JP5004407B2 (ja) 2012-08-22
HRP20040383B1 (hr) 2012-08-31
EP2368567A1 (de) 2011-09-28
DE10153601A1 (de) 2003-05-22
US20170051268A1 (en) 2017-02-23
CA2465792A1 (en) 2003-05-08
US8119597B2 (en) 2012-02-21
ES2382224T3 (es) 2012-06-06
SI1997510T1 (sl) 2012-06-29
NZ545414A (en) 2008-09-26
PL208343B1 (pl) 2011-04-29
PT1997510E (pt) 2012-05-21
CN1592634A (zh) 2005-03-09
HRP20040383A2 (en) 2005-08-31
CY1112957T1 (el) 2016-04-13
WO2003037363A2 (de) 2003-05-08
ATE547115T1 (de) 2012-03-15
CY1109648T1 (el) 2014-08-13
SG148034A1 (en) 2008-12-31
EA201000386A1 (ru) 2011-06-30
IL205695A0 (en) 2010-11-30
EA200400624A1 (ru) 2004-10-28
KR100816221B1 (ko) 2008-03-24
ZA200403285B (en) 2005-07-27
EP1441757B1 (de) 2008-07-23
AU2002350660B2 (en) 2008-04-10
US20090004176A1 (en) 2009-01-01
EA013707B1 (ru) 2010-06-30
US8071091B2 (en) 2011-12-06
WO2003037363A3 (de) 2003-09-18
ES2311070T3 (es) 2009-02-01
NO20042262D0 (no) 2004-06-01
DK1441757T3 (da) 2008-11-17
JP2009137983A (ja) 2009-06-25
AU2002350660C1 (en) 2008-10-09
EP1997510A8 (de) 2011-04-13
EP1997510A1 (de) 2008-12-03
MXPA04004155A (es) 2005-03-31
DK1997510T3 (da) 2012-05-21
US20090263373A1 (en) 2009-10-22
NZ532903A (en) 2006-10-27
NO20042262L (no) 2004-06-01
EA200801714A1 (ru) 2008-12-30
US20130039902A1 (en) 2013-02-14
CY1108446T1 (el) 2014-04-09
US20050048027A1 (en) 2005-03-03
EP1441757A2 (de) 2004-08-04
CN100446810C (zh) 2008-12-31
ATE440614T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
IL205695A0 (en) Compositions containing dspa alpha 1 for the treatment of stroke
DE60218633D1 (de) Inhibitoren von cruzipain und anderen cysteinproteasen
DE60040345D1 (de) VERFAHREN ZUR HERSTELLUNG EINER REVERSIBEL INAKTIVEN, ANGESäUERTEN PLASMINZUSAMMENSETZUNG
TR199902692T2 (xx) Serin proteaz inhibit�rleri.
NO910811L (no) Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper.
DK0691858T3 (da) Tokomponent fibrinklæber
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
EP1008348A4 (en) THROMBOLYTIC AGENT
WO2002057248A3 (en) Inhibitors of cruzipain and other cysteine proteases
ATE253937T1 (de) Thrombolytische zusammensetzungen
JPS6434921A (en) Preventive and remedy for thrombosis